Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.59 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.57 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.57 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.57 |
| ▸ | CHKA | P35790 | 1/20 | 0.52 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12563565 | 0.99 | CYP2D6 (0.69) | CYP2D6CYP2C9HIF1ASMN1; SMN2MEN1 | |
| SCHEMBL20209837 | 0.97 | CYP2D6 (0.62) | CYP2D6CYP2C9HIF1ASMN1; SMN2MEN1 | |
| SCHEMBL13150524 | 0.90 | MEN1 (0.56) | CYP2D6CYP2C9HIF1ASMN1; SMN2MEN1 | |
| SCHEMBL10145077 | 0.89 | ALDH1A1 (0.60) | CYP2D6CYP2C9HIF1ASMN1; SMN2MEN1 | |
| SCHEMBL2002699 | 0.89 | MEN1 (0.57) | CYP2D6CYP2C9HIF1ASMN1; SMN2MEN1 | |
| SCHEMBL31721209 | 0.89 | ALDH1A1 (0.60) | CYP2D6CYP2C9HIF1ASMN1; SMN2MEN1 | |
| SCHEMBL6733775 | 0.88 | HIF1A (0.57) | CYP2D6CYP2C9HIF1ASMN1; SMN2MEN1 | |
| SCHEMBL1512308 | 0.87 | CHRM3 (0.72) | SMN1; SMN2MEN1ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL30512200 | 0.87 | ALDH1A1 (0.62) | SMN1; SMN2MEN1ALDH1A1KMT2AHSD17B10 | |
| SCHEMBL1013481 | 0.87 | ALDH1A1 (0.62) | SMN1; SMN2MEN1ALDH1A1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3840832-B1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | BENEVOLENTAI BIO LTD (GB) | 2023-10-11 | — | — | EP | disclosed |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2021-10-28 | — | — | US | disclosed |
| WO-2021148805-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | BENEVOLENTAI BIO LIMITED (GB) | 2021-07-29 | — | — | WO | disclosed |
| US-10934299-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3623372-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-03-18 | — | — | EP | disclosed |
| WO-2020039209-A1 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | BENEVOLENTAI BIO LIMITED (GB) | 2020-02-27 | — | — | WO | disclosed |
| CN-107406451-B | Pyrrolopyrimidines and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | 福马治疗股份有限公司 | 2019-12-17 | — | — | CN | disclosed |
| EP-3240791-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-10377760-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| EP-2305250-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2011-04-06 | — | — | EP | disclosed |
| US-20090163503-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-06-25 | — | — | US | disclosed |
| EP-1963326-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007068637-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | ASTEX THERAPEUCTICS, LIMITED (US) | 2007-06-14 | — | — | US | disclosed |
| EP-1648426-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005002552-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| EP-1070708-B1 | Triazole derivatives | HOFFMANN LA ROCHE (CH) | 2004-01-14 | — | — | EP | disclosed |
| US-6265426-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | HOFFMANN-LA ROCHE INC. | 2001-07-24 | — | — | US | disclosed |
| EP-1070708-A1 | Triazole and imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377760-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, UBXN1 | CYP2D6 2061/4885CYP2C9 2518/4885HIF1A 2482/4885 |
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, UBXN1 | CYP2D6 1846/4885CYP2C9 2466/4885HIF1A 2602/4885 |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, UBXN1 | CYP2D6 1846/4885CYP2C9 2466/4885HIF1A 2602/4885 |
| US-20090163503-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K5, MAP3K19, MAP3K3 | CYP2D6 2006/4885CYP2C9 1793/4885HIF1A 2664/4885 |
| US-20070135477-A1 | Benzimidazole derivatives and their use as protein kinases inhibitors | CDK1, AURKA, CDK2 | CYP2D6 2783/4885CYP2C9 2747/4885HIF1A 1097/4885 |
| US-10934299-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, UBXN1 | CYP2D6 1846/4885CYP2C9 2466/4885HIF1A 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.